Publication | Closed Access

A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome

InflammationThrombosisCardiovascular DiseaseAtherosclerosisVascular InflammationMedicineCardiovascular PharmacologyPlacebo-controlled StudyVascular BiologyPharmacotherapyAnesthesiology5-Lipoxygenase InhibitorAcute Myocardial InfarctionPharmacologyCardiologyCoronary Artery DiseaseOxidative StressMyocardial Infarction